920023-55-8

Basic information

• Product Name: TERT-BUTYL 3,4-DIHYDRO-2HSPIRO[ ISOQUINOLINE-1,4'- PIPERIDINE]-1'-CARBOXYLATE
• Synonyms: TERT-BUTYL 3,4-DIHYDRO-2HSPIRO[ ISOQUINOLINE-1,4'- PIPERIDINE]-1'-CARBOXYLATE;tert-Butyl 2,3-dihydrospiro[isoindole-1,4'-piperidine]-1'-carboxylate;ZXEHOZNMWWBHDT-UHFFFAOYSA-N
• CAS NO: 920023-55-8
• Molecular Formula: C18H26N2O2
• Molecular Weight: 302.41124
• Mol File: 920023-55-8.mol

Chemical Properties

• Boiling Point: 406.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• PKA: 8.71±0.20(Predicted)
• CAS DataBase Reference: TERT-BUTYL 3,4-DIHYDRO-2HSPIRO[ ISOQUINOLINE-1,4'- PIPERIDINE]-1'-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTYL 3,4-DIHYDRO-2HSPIRO[ ISOQUINOLINE-1,4'- PIPERIDINE]-1'-CARBOXYLATE(920023-55-8)
• EPA Substance Registry System: TERT-BUTYL 3,4-DIHYDRO-2HSPIRO[ ISOQUINOLINE-1,4'- PIPERIDINE]-1'-CARBOXYLATE(920023-55-8)

Safety Data

• Hazardous Substances Data: 920023-55-8(Hazardous Substances Data)

Upstream product

• 920023-54-7 1'-tert-butyloxycarbonylspiro[isoindoline-1,4'-piperidine]-3-one 
• 13292-87-0 dimethylsulfide borane complex 
• 1510865-53-8 tert-butyl 4-(2-((4-methoxyphenyl)sulfonyl)hydrazono)piperidine-1-carboxylate 
• 745835-05-6 2-(azidomethyl)phenylboronic acid 
• 91983-14-1 2-bromomethylphenylboronic acid 
• 937254-73-4 1'-tert-butyloxycarbonyl-2-(4-methoxybenzyl)-2',3'-dihydro-1'H-spiro[isoindoline-1,4'-pyridine]-3-one 
• 609-67-6 2-Iodobenzoyl chloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Relevant articles and documents

Construction of NH-Unprotected Spiropyrrolidines and Spiroisoindolines by [4+1] Cyclizations of γ-Azidoboronic Acids with Cyclic N-Sulfonylhydrazones

The reactions of N-sulfonylhydrazones derived from cyclic ketones with γ-azidopropylboronic acid and 2-(azidomethyl)phenylboronic acid give rise to spirocyclic pyrrolidines and spiroisoindolines, respectively. The reactions proceed without the need of any transition-metal catalyst through a domino process that comprises the formation of a Csp3-C and a Csp3-N bond of the former hydrazonic carbon. The scope of the reaction has been explored by the preparation of over 50 examples of NH-unprotected spirocyclic derivatives. Importantly, this methodology could be applied for the preparation of alkaloid steroids from steroid N-tosylhydrazones.

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Provided are 2-(piperidin-1-yl)pyrimidin-4(3H)-ones or pharmaceutically acceptable salts thereof, each characterized by having a 1,8-diazaspiro[4.5]deca-3-ene, 1-oxa-8-azaspiro[4.5]deca-3-ene, 2,8-diazaspiro[4.5]deca-3-ene, 2-oxa-8-azaspiro[4.5]deca-3-ene, 2,9-diazaspiro[5.5]undeca-3-ene, 1-oxa-9-azaspiro[5.5]undeca-3-ene, 1,9-diazaspiro[5.5]undeca-4-ene, or 3,9-diazaspiro[5.5]undeca-1-ene structure represented by the following general formula (1):

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.